Sensus Healthcare(US:SRTS)2019-08-10 00:41Financial Data and Key Metrics Changes - Revenues for Q2 2019 were $7.5 million, up 23% from Q2 2018, and significantly above Q1 2019 revenues of $5.4 million [20][21] - Gross profit for Q2 2019 was $4.9 million, representing 66.1% of revenues, compared to $3.9 million or 65.1% for Q2 2018 [20][21] - Net income for Q2 2019 was $0.1 million or $0.01 per diluted share, compared to a net loss of $0.5 million or $0.04 per share for Q2 2018 [25] Business Line Data and Key Metrics Changes - The company shipped 22 systems in total during Q2 2019, including 17 SRT-100 Vision systems, indicating a recovery in sales [7][20] - The SRT-100 Vision system sales were a significant contributor to revenue growth, with a focus on expanding the customer base to large dermatology practices and hospital centers [9][32] Market Data and Key Metrics Changes - The company is targeting a market consisting of approximately 14,000 dermatologists and 1,000 Mohs surgeons in the U.S., representing over 7,500 offices [32] - The inclusion of SRT products in Premier Healthcare Alliance's approved products list is expected to enhance market penetration [13] Company Strategy and Development Direction - The company is focused on expanding its SRT customer base and enhancing its product offerings, including the unique Sentinel IP product for asset management [10][12] - The Sculptura Modulated Robotic Brachytherapy system is being actively marketed, with collaborations with medical institutions to support its launch [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of the year, citing a resumption of sales to a key customer and ongoing efforts to work with multisite customers [32] - The company anticipates positive developments in reimbursement codes, particularly with the main code 77401 scheduled for revaluation in 2021 [17][19] Other Important Information - Cash and investments as of June 30, 2019, were $16.8 million, an increase from $15.4 million at the end of 2018, with no outstanding borrowings [27] - The company expects to increase sales and marketing expenses in Q3 2019 due to trade show costs and the Sculptura launch [22] Q&A Session Summary Question: Changes with the large turnkey partner - Management confirmed the renewal of the contract with SkinCure and ongoing discussions regarding terms and conditions [38] Question: Resolution of DOJ CID from a few years back - Management reported no follow-up news or issues related to the DOJ CID [44] Question: Timeline for Sculptura data from institutions - Management indicated ongoing collaboration with UPenn and efforts to gather data ahead of the ASTRO conference [45][46] Question: Expectations for aesthetic products from Israel - Management stated that aesthetic products are on track for FDA approval, with a focus on quality and differentiation [52] Question: Current reimbursement rates and future expectations - Current reimbursement for SRT is approximately $2,000 to $2,100 for an episode of care, with expectations for revaluation in 2021 [57][58]